Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Taps DNAnexus to Support Cell-Free Assay, Other Activities

NEW YORK (GenomeWeb) – Molecular diagnostics company CareDx has selected DNAnexus' cloud-based bioinformatics infrastructure to handle data from its proprietary next-generation sequencing-based cell-free DNA transplant assay, which is scheduled for release later this year.

DNAnexus' platform will also support ongoing research and development activities at CareDx as well as the company's clinical trials and registries, the partners said.

John Sninsky, CareDx's chief scientific officer, said in a statement that his firm selected the DNAnexus platform because it reduced the cost, time, and technical challenges that the company would have faced if it chose to develop an on-premise solution. "[T]he platform offers rapid implementation of a computational analysis solution, which was critical for our cfDNA D-OAR heart transplant registry and DART kidney transplant clinical trial," he said.

"The compliant cloud-based DNAnexus platform, with full versioning and auditing will play a critical role in expediting our cfDNA assay efforts," Dave Wexler, CareDx's senior director, clinical informatics and automation engineering, added, "enabling us to deliver our novel surveillance management solution to the transplant setting and scale our NGS offerings in the future."